Market Research Logo

Anti-Infectives: World Market, 2nd. Ed., Vol. I: Antifungals

Over one billion people suffer from fungal infections worldwide, and this number is growing Though Athlete's foot, dandruff, vaginal yeast infection and fungal nail make up the bulk of these cases, there has been a steady increase in the incidence of more serious infections.

This is partially due to the widespread use of antibiotics, which eliminate or decrease fungi-killing bacteria. The increased number of individuals with reduced immune responses caused by AIDS or the effects of chemotherapy has also been a factor. These are part of the factors that have lead to nearly 6-billion dollar antifungal drug industry.

Anti-Infectives, Second Edition, Volume I: Antifungals is a comprehensive review of the market for anti fungal drugs. This is the first volume of Kalorama Information’s 2nd edition of its popular three-part series on anti-infective markets. The report focuses on two segments of antifungal treatment: systemic and topical. The report covers both currently marketed and late stage development antifungal products in detail.

For both the systemic and topical antifungal markets, this report includes:

  • U.S. and World Revenues
  • Forecasts to 2011.
  • Overview and Incidence Data
  • Description of Products on the Market
  • Review of Products in Development
  • Competitive Analysis of Leading Providers.
  • 10 Key Issues and Trends facing the antifungal industry

Revenues for each segment were generated using dollar and unit sales for each product. All market data pertain to the world market at the manufacturers’ level. Revenues and market share of major brands such as Lamisil, Diflucan, Sporanox, Cancidas, Vfend, and others are included.

Competitive analysis is provided for the year 2006. The forecasted market analysis for 2004-2011 was based on probability of approval and sales of products in late stage development, product marketing, and demographic trends.

As part of Kalorama's trusted information-gathering process, the information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information and developing forecasts.

For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.


  • Executive Summary
    • INTRODUCTION
    • SCOPE AND METHODOLOGY
    • SIZE AND GROWTH OF THE MARKET
      • Table The World Market for Antifungal Drugs 2004-2011
    • ISSUES AND TRENDS AFFECTING THE MARKET
    • LEADING COMPETITORS
  • Introduction
    • OVERVIEW
      • Introduction to Pathogens
      • Antimicrobial Spectrum
      • Bacterial Resistance
      • Principles of Anti-infective Therapy
      • Combination Therapy and Prophylactic Use
    • FUNGAL INFECTIONS
    • TYPES OF FUNGAL INFECTIONS
      • Superficial
      • Systemic
    • DEMOGRAPHICS AND STATISTICS
      • Table Estimated World and U.S. Incidence of Fungal Infections (thousands)
      • Table World Population by Selected Geographical Region, 2006-2050
      • Table Estimated World Population by Age and Geographical Region, 2006
      • Table World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2006
  • Systemic Antifungal Drugs
    • OVERVIEW
    • DESCRIPTION OF PRODUCTS
      • Allylamines
        • Table Allylamines
      • Azoles
        • Table Azoles
      • Polyene Macrolides
        • Table Polyene Macrolides
      • Miscellaneous Antifungals
        • Table Miscellaneous Antifungals
    • GENERIC DRUG IMPACT AND AVAILABILITY
      • Table New Generic Drug Approvals for Systemic Antifungals, United States, 2004-2006
    • RESEARCH AND DEVELOPMENT
      • Table Systemic Antifungal Drugs in Development
    • MARKET SIZE AND GROWTH
      • Table The Market for Systemic Antifungal Drugs 2004-2011
      • Table Systemic Antifungal Drug Market by Product Type (Allylamines, Azoles, Polyene Macrolides, and Others) 2004-2010
      • Table Systemic Antifungal Drug Market Share by Product Type 2006 and 2011
      • Table Systemic Antifungal Drug Market Estimated Products Sales by Infection Type, 2006
      • Table Systemic Antifungal Drug Market Estimated Products Sales by Geographic Region, 2006
    • COMPETITIVE ANALYSIS
      • Table Systemic Antifungal Drug Market Estimated Revenues and Market Share of Leading Suppliers 2006
      • Table Systemic Antifungal Drug Market Projected Revenues and Market Share of Leading Suppliers 2011
      • Table Systemic Antifungal Drug Market Estimated Sales of Top Antifungal Products 2006
  • Topical Antifungal Drugs
    • OVERVIEW
    • DESCRIPTION OF PRODUCTS
      • Allylamines
        • Table Allyamines
      • Azoles
        • Table Topical Azoles
      • Polyene Macrolides
        • Table Polyene Macrolides
      • Miscellaneous Antifungals
        • Table Miscellaneous Antifungals
    • GENERIC DRUG IMPACT AND AVAILABILITY
      • Table New Generic Drug Approvals for Topical Antifungals, United States, 2004-2006
    • RESEARCH AND DEVELOPMENT
      • Table Topical Antifungal Drugs in Development
    • MARKET SIZE AND GROWTH
      • Table Topical Antifungal Drug Market, 2004-2011 (in millions of dollars at the manufacturers level)
      • Table Topical Antifungal Drug Market by Type, 2004-2011 (in millions of dollars at the manufacturers level)
      • Table Topical Antifungal Drug Market Share by Product Type 2006 and 2011
      • Table Topical Antifungal Drug Market Estimated Products Sales by Infection Type, 2006
      • Table Topical Antifungal Drug Market Estimated Products Sales by Geographic Region, 2006
    • COMPETITIVE ANALYSIS
      • Table Topical Antifungal Drug Market Estimated Revenues and Market Share of Leading Suppliers 2006
      • Table Topical Antifungal Drug Market Projected Revenues and Market Share of Leading Suppliers 2011
      • Table Topical Antifungal Drug Market Estimated Sales of Top Antifungal Products 2006
  • Issues and Trends Affecting the Antifungal Market
    • INTRODUCTION
    • FUNGAL INFECTIONS AND IMMUNOCOMPROMISED PATIENTS
    • REIMBURSEMENT
    • INFECTION IMAGING
    • EXPANDED USE OF AZOLES
    • DRUG RESISTANCE AND INTERACTIONS
    • STANDARDIZED SUSCEPTIBILITY TESTING
    • GENERIC IMPACT AND AVAILABILITY
      • Table New Generic Drug Approvals for Antifungals, United States, 20042006
    • IMPORTANCE OF DRUG DELIVERY
    • RX-TO-OTC SWITCHES
      • Table Selected Antifungal Rx-to-OTC Switches
    • THE ANTIFUNGAL MARKET AND ENCHIOCANDINS
  • Antifungal Drugs: Total Market Size and Forecast
    • OVERVIEW
    • TOTAL MARKET SIZE AND FORECAST
      • Table The World Market for Antifungal Drugs 2004-2011
      • Table World Antifungal Drug Market by Type (Topical vs Systemic) 2004-2011
      • Table The World Market for Antifungal Drugs Revenues by Type (Systemic vs Topical) 2006 and 2011
  • Corporate Profiles
    • INTRODUCTION
    • ASTELLAS PHARMA INC.
    • BARRIER THERAPEUTICS, INC.
    • JOHNSON & JOHNSON GROUP
    • MERCK & COMPANY, INC.
    • NOVARTIS PHARMACEUTICALS CORPORATION
    • PFIZER, INC.
    • SCHERING-PLOUGH CORPORATION
  • Company Directory

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report